Citi upgraded PTC Therapeutics (PTCT) to Neutral from Sell with a price target of $40, down from $50. The company’s Q1 revenue came in above consensus, in part driven by Emflaza sales ahead of expected volume erosion to biosimilars, the analyst tells investors in a research note. The firm says Street expectations have re-aligned closer to its numbers, while PTC has an opportunity into the summer across two potential approvals and launches in disease areas with unmet need. As such, the stock’s risk/reward is now more balanced than before into the potential Sephience approval, contends Citi.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTCT:
- PTC Therapeutics Reports Strong Q1 2025 Results
- PTC Therapeutics: Balancing Strategic Success with Regulatory Uncertainty – A Hold Rating Analysis
- PTC Therapeutics Reports Strong Q1 2025 Financial Results
- PTC Therapeutics narrows FY25 revenue view to $650M-$800M from $600M-$800M
- PTC Therapeutics reports Q1 EPS $10.04 may not compare with consensus (7c)